Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
58 hedge funds and large institutions have $11.5M invested in Oncternal Therapeutics, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 24 reducing their positions, and 10 closing their positions.
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
0% more funds holding
Funds holding: 58 → 58 (0)
33% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 24
35% less capital invested
Capital invested by funds: $17.8M → $11.5M (-$6.25M)
46% less call options, than puts
Call options by funds: $266K | Put options by funds: $497K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$620K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$549K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$128K |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$103K |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
+$98.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.18M |
| 2 |
VM
VHCP Management
New York
|
-$1.01M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$597K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$501K |
| 5 |
D.E. Shaw & Co
New York
|
-$496K |
ONCT Hedge Fund Activity: Q4 2013 in Review
58 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2013, worth a combined $11.5M — down 35% from $17.8M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ONCT positions and 10 closed out — a net gain of 1 holder — while 16 added to existing stakes and 24 trimmed.
The largest buyer was TFS Capital, adding an estimated $620K. The largest seller was BlackRock Fund Advisors, cutting an estimated $1.18M.
- 58 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2013, unchanged from Q3 2013.
- Funds reported $11.5M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2013, down 35% quarter-over-quarter.
- 11 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2013 and 10 closed out, a net change of +1 holder.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2013 was TFS Capital, an estimated $620K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2013 was BlackRock Fund Advisors, an estimated $1.18M sold.
Based on aggregated 13F filings for Q4 2013.